Skip to main content
TipRanks
Go Ultimate75% OFF

MedCap AB (MCAP) AI Stock Analysis

0 Followers
SE:MCAP

MedCap AB

(Nasdaq OMX AB:MCAP)

Select Model
Rating:74Outperform
Price Target:SEK 632.00â–²(16.71% Upside)
Action:reiterated
Date:10/27/26

The score is driven primarily by strong financial performance (solid margins, positive growth, healthy ROE with moderate leverage). Technicals add support via a clear uptrend and positive momentum indicators. These positives are tempered by a relatively high P/E valuation and some variability in gross profitability and operating cash conversion.

Positive Factors
Profitable revenue growthPositive revenue expansion alongside healthy EBIT, EBITDA, and net margins indicates that MedCap’s portfolio companies are converting growth into substantial operating profitability. This supports reinvestment, strengthens the earnings base, and suggests the group has durable economic value beyond short-term sales fluctuations.
Negative Factors
Uneven operating cash conversionAlthough free cash flow is generally good, weaker and uneven operating cash conversion means earnings may not consistently arrive as cash within the same periods. This can create working-capital volatility, complicate portfolio funding decisions, and reduce flexibility during periods of faster investment or weaker trading.

MedCap AB (MCAP) vs. iShares MSCI Sweden ETF (EWD)

-20%-10%0%10%20%30%SE:MCAP-1.37%EWD+8.63%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 8.30B
Dividend Yield
―
Average Volume (3M)
19.37K
Price to Earnings (P/E)
29.6
Beta (1Y)
0.43
Revenue Growth
16.54%
EPS Growth
39.10%
Country
Sweden
Employees
647
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

MedCap AB Business Overview & Revenue Model

Company Description

MedCap AB (publ) operates as a private equity firm, employing a diverse array of investment strategies including secondary direct deals, later-stage funding, industry consolidation, growth capital provision, engagement with middle-market and mature b...

How the Company Makes Money

MedCap makes money primarily through the operating earnings of its consolidated portfolio companies and the value creation of those businesses over time. The core revenue engine sits in the subsidiaries/portfolio companies, which generate sales by pr...

MedCap AB Financial Statement Overview

Summary

Strong overall fundamentals supported by solid profitability (TTM gross margin ~38%, EBIT margin ~16%, EBITDA margin ~24%, net margin ~12%) and positive TTM revenue growth. Balance sheet is sound with moderate leverage (TTM debt-to-equity ~0.26) and consistently strong ROE (TTM ~17.5%). Offsets include volatility in gross profitability across periods and uneven operating cash conversion (TTM operating cash flow coverage ~0.70), which adds near-term cash flow uncertainty.

Income Statement

82Very Positive

Balance Sheet

79Positive

Cash Flow

74Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.32B2.11B1.81B1.59B1.11B916.30M
Gross Profit882.00M321.00M1.06B926.40M462.40M369.80M
EBITDA557.90M473.80M396.00M341.90M256.20M201.90M
Net Income274.40M219.80M207.40M172.20M117.60M96.50M
Balance Sheet
Total Assets2.80B2.61B1.99B1.66B1.43B1.17B
Cash, Cash Equivalents and Short-Term Investments272.80M370.40M370.10M188.20M236.20M139.70M
Total Debt437.70M482.90M358.00M261.20M340.00M256.90M
Total Liabilities1.09B1.15B703.20M635.10M570.60M471.80M
Stockholders Equity1.71B1.45B1.28B1.02B856.30M696.00M
Cash Flow
Free Cash Flow374.60M280.50M293.80M188.70M41.20M55.40M
Operating Cash Flow422.00M342.70M360.00M228.00M85.50M116.30M
Investing Cash Flow-305.90M-391.30M-128.80M-152.30M-56.10M-64.80M
Financing Cash Flow-215.70M52.20M-46.10M-119.70M61.20M-64.10M

MedCap AB Technical Analysis

Technical Analysis SentimentNeutral
Last Price541.50

Price Trends

50DMA538.52Positive
100DMA540.06Positive
200DMA518.53Positive

Market Momentum

MACD1.84Positive
RSI46.24Neutral
STOCH19.79Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MCAP, the sentiment is Neutral. The current price of 541.50 is below the 20-day moving average (MA) of 551.80, above the 50-day MA of 538.52, and above the 200-day MA of 518.53, indicating a neutral trend. The MACD of 1.84 indicates Positive momentum. The RSI at 46.24 is Neutral, neither overbought nor oversold. The STOCH value of 19.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:MCAP.

MedCap AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:MCAP against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:SECT.BSE:SECT.B74OutperformSEK 65.68B100.9830.26%0.70%13.94%5.70%
SE:MCAPSE:MCAP74OutperformSEK 8.30B29.6217.50%―16.54%39.10%
SE:GETI.BSE:GETI.B67NeutralSEK 76.26B26.649.13%1.72%-3.90%37.73%
SE:XVIVOSE:XVIVO64NeutralSEK 6.17B47.955.89%―17.83%330.94%
SE:VITRSE:VITR63NeutralSEK 15.90B-3.14-61.57%0.96%-1.94%-1223.74%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:SEDANASE:SEDANA49NeutralSEK 889.07M-24.90-3.88%―0.42%15.03%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%SE:MCAPSE:GETI.BSE:VITRSE:XVIVOSE:SECT.BSE:SEDANADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:MCAP and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:MCAPMedCap AB541.50-2.50-0.46%
SE:GETI.BGetinge AB (UK)276.8071.2534.66%
SE:VITRVitrolife AB115.10-29.81-20.57%
SE:XVIVOXvivo Perfusion AB196.1016.309.07%
SE:SECT.BSectra AB Class B330.2047.0616.62%
SE:SEDANASedana Medical AB8.65-1.35-13.50%

MedCap AB Corporate Events

MedCap Delivers Strong Margin Expansion and Earnings Growth in Third Quarter

Oct 23, 2026

MedCap AB reported strong third-quarter performance, with net sales rising 13 percent to SEK 566.7 million and EBITA surging 72 percent to SEK 154.7 million, driven partly by adjustments to contingent consideration liabilities. Even excluding items a...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 27, 2026